Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Mar;17(4):789-790.
doi: 10.1016/j.cgh.2018.06.035. Epub 2018 Jun 30.

Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury

Jawad Ahmad  1 , Simona Rossi  2 , Shuchi K Rodgers  2 , Marwan Ghabril  2 , Robert J Fontana  2 , Andrew Stolz  2 , Paul H Hayashi  2 , Huiman Barnhart  2 , David E Kleiner  2 , Einar S Bjornsson  2
Affiliations
Observational Study

Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury

Jawad Ahmad et al. Clin Gastroenterol Hepatol. 2019 Mar.

Abstract

Drug-induced liver injury can lead to changes of the biliary tree that resemble sclerosing cholangitis. These changes can be seen on magnetic resonance cholangiopancreatography. Idiosyncratic drug-induced liver injury (DILI) has a variable presentation including cholestatic liver injury,1 in which case magnetic resonance imaging (MRI) is often performed to exclude pancreaticobiliary causes of obstruction. Sclerosing cholangitis (SC)-like changes on imaging have been described anecdotally with DILI.2,3 A recent study of 25 consecutive, unselected DILI patients found that 10% had SC-like changes on magnetic resonance cholangiopancreatography (MRCP).4 The aim of the current study was to identify the clinical features of patients enrolled in the U.S. Drug Induced Liver Injury Network (DILIN) prospective study who had SC-like changes on MRCP.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest:

JA, SKR, MG, AS, HB, PHH, ESB. No disclosures

RJF: I have received research support from Gilead Sciences and BMS. I have provided consulting services to Alynam and Abbvie.

SR: BMS, Gilead

Figures

Figure 1:
Figure 1:
Coronal MRCP image demonstrating a focal hilar stricture and left hepatic duct stricture
See this image and copyright information in PMC

References

    1. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246–59. - PMC - PubMed
    1. Sandrasegaran K, Alazmi WM, Tann M, et al. Chemotherapy-induced sclerosing cholangitis. Clin Radiol. 2006;61:670–8. - PubMed
    1. Horsley-Silva JL, Dow EN, Menias CO et al. Docetaxel Induced Sclerosing Cholangitis. Dig Dis Sci 2015;60:3814–6. - PubMed
    1. Gudnason HO, Björnsson HK, Gardarsdottir M, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liv Dis 2015;47:502–7. - PubMed
    1. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55–68. - PMC - PubMed

Publication types